Literature DB >> 22711889

Cutting edge: impaired MHC class I expression in mice deficient for Nlrc5/class I transactivator.

Amlan Biswas1, Torsten B Meissner, Taro Kawai, Koichi S Kobayashi.   

Abstract

MHC class I and class II are crucial for the adaptive immune system. Although regulation of MHC class II expression by CIITA has long been recognized, the mechanism of MHC class I transactivation has been largely unknown until the recent discovery of NLRC5/class I transactivator. In this study, we show using Nlrc5-deficient mice that NLRC5 is required for both constitutive and inducible MHC class I expression. Loss of Nlrc5 resulted in severe reduction in the expression of MHC class I and related genes such as β(2)-microglobulin, Tap1, or Lmp2, but did not affect MHC class II levels. IFN-γ stimulation could not overcome the impaired MHC class I expression in Nlrc5-deficient cells. Upon infection with Listeria monocyogenes, Nlrc5-deficient mice displayed impaired CD8(+) T cell activation, accompanied with increased bacterial loads. These findings illustrate critical roles of NLRC5/class I transactivator in MHC class I gene regulation and host defense by CD8(+) T cell responses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22711889      PMCID: PMC3578426          DOI: 10.4049/jimmunol.1200064

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  The bare lymphocyte syndrome and the regulation of MHC expression.

Authors:  W Reith; B Mach
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.

Authors:  Y Itoh-Lindstrom; J F Piskurich; N J Felix; Y Wang; W J Brickey; J L Platt; B H Koller; J P Ting
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

3.  Induction of MHC class I expression by the MHC class II transactivator CIITA.

Authors:  B K Martin; K C Chin; J C Olsen; C A Skinner; A Dey; K Ozato; J P Ting
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

4.  Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA.

Authors:  S J Gobin; A Peijnenburg; V Keijsers; P J van den Elsen
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

5.  Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression.

Authors:  C H Chang; S Guerder; S C Hong; W van Ewijk; R A Flavell
Journal:  Immunity       Date:  1996-02       Impact factor: 31.745

6.  Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).

Authors:  V Steimle; L A Otten; M Zufferey; B Mach
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

Review 7.  The biochemistry and cell biology of antigen processing and presentation.

Authors:  R N Germain; D H Margulies
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

8.  CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter.

Authors:  G W Beresford; J M Boss
Journal:  Nat Immunol       Date:  2001-07       Impact factor: 25.606

9.  Mice lacking the transcription factor CIITA--a second look.

Authors:  G S Williams; M Malin; D Vremec; C H Chang; R Boyd; C Benoist; D Mathis
Journal:  Int Immunol       Date:  1998-12       Impact factor: 4.823

10.  Class II-antigen-negative patient and mutant B-cell lines represent at least three, and probably four, distinct genetic defects defined by complementation analysis.

Authors:  B Bénichou; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

View more
  44 in total

Review 1.  NLRC5/CITA: A Key Player in Cancer Immune Surveillance.

Authors:  Sayuri Yoshihama; Saptha Vijayan; Tabasum Sidiq; Koichi S Kobayashi
Journal:  Trends Cancer       Date:  2017-01-10

2.  Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8+ T Cell Function and Impaired Viral Clearance.

Authors:  Christopher R Lupfer; Kate L Stokes; Teneema Kuriakose; Thirumala-Devi Kanneganti
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

3.  NLRC5/MHC class I transactivator is a target for immune evasion in cancer.

Authors:  Sayuri Yoshihama; Jason Roszik; Isaac Downs; Torsten B Meissner; Saptha Vijayan; Bjoern Chapuy; Tabasum Sidiq; Margaret A Shipp; Gregory A Lizee; Koichi S Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

4.  Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells.

Authors:  Xuancheng Guo; Taixiang Liu; Hengfei Shi; Jingjing Wang; Ping Ji; Hongwei Wang; Yayi Hou; Ren Xiang Tan; Erguang Li
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

Review 5.  Expression regulation and function of NLRC5.

Authors:  Yikun Yao; Youcun Qian
Journal:  Protein Cell       Date:  2013-03-13       Impact factor: 14.870

6.  NLRP2 is a suppressor of NF-ƙB signaling and HLA-C expression in human trophoblasts†,‡.

Authors:  Tamara Tilburgs; Torsten B Meissner; Leonardo M R Ferreira; Arend Mulder; Kiran Musunuru; Junqiang Ye; Jack L Strominger
Journal:  Biol Reprod       Date:  2017-04-01       Impact factor: 4.285

7.  PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.

Authors:  Hyungsoo Kim; Heejung Kim; Yongmei Feng; Yan Li; Hironari Tamiya; Stefania Tocci; Ze'ev A Ronai
Journal:  Sci Transl Med       Date:  2020-07-08       Impact factor: 17.956

8.  The Obligate Intracellular Bacterium Orientia tsutsugamushi Targets NLRC5 To Modulate the Major Histocompatibility Complex Class I Pathway.

Authors:  Kyle G Rodino; Haley E Adcox; Rebecca K Martin; Vaidehi Patel; Daniel H Conrad; Jason A Carlyon
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

Review 9.  Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.

Authors:  Saptha Vijayan; Tabasum Sidiq; Suhail Yousuf; Peter J van den Elsen; Koichi S Kobayashi
Journal:  Immunogenetics       Date:  2019-01-31       Impact factor: 2.846

Review 10.  Listeria monocytogenes and the Inflammasome: From Cytosolic Bacteriolysis to Tumor Immunotherapy.

Authors:  Erin Theisen; John-Demian Sauer
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.